171 related articles for article (PubMed ID: 21030993)
1. An audience with Patrick Vallance.
Vallance P
Nat Rev Drug Discov; 2010 Nov; 9(11):834. PubMed ID: 21030993
[No Abstract] [Full Text] [Related]
2. An audience with...John Reed.
Reed J; Mullard A
Nat Rev Drug Discov; 2014 Mar; 13(3):170-1. PubMed ID: 24577393
[No Abstract] [Full Text] [Related]
3. Cancer charity sees success re-prioritizing industry's shelved compounds.
Mullard A
Nat Rev Drug Discov; 2014 May; 13(5):319-21. PubMed ID: 24781536
[No Abstract] [Full Text] [Related]
4. Vas Narasimhan.
Narasimhan V; Mullard A
Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275
[No Abstract] [Full Text] [Related]
5. Partnering for therapeutics discovery.
Colvis CM; Devaney S; Brady LS; Hudson KL
Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
[No Abstract] [Full Text] [Related]
6. Q&A: Bernard Munos.
Bender E
Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
[No Abstract] [Full Text] [Related]
7. Virtual drug discovery with the rise of Chinese CROs.
Zhang MQ
Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
[No Abstract] [Full Text] [Related]
8. Could pharma open its drug freezers?
Mullard A
Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
[No Abstract] [Full Text] [Related]
9. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
[No Abstract] [Full Text] [Related]
10. 2011 in reflection.
Mullard A
Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
[No Abstract] [Full Text] [Related]
11. Menelas Pangalos. Interview by Asher Mullard.
Mullard A
Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338
[No Abstract] [Full Text] [Related]
12. Ian Tomlinson.
Tomlinson I
Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
[No Abstract] [Full Text] [Related]
13. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
[No Abstract] [Full Text] [Related]
14. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
Smith BJ
Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
[No Abstract] [Full Text] [Related]
15. The risky business of drug development in neurology.
Craven R
Lancet Neurol; 2011 Feb; 10(2):116-7. PubMed ID: 21256451
[No Abstract] [Full Text] [Related]
16. The long march of antisense.
Jones D
Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
[No Abstract] [Full Text] [Related]
17. Jay Bradner.
Nat Rev Drug Discov; 2017 Mar; 16(4):232-233. PubMed ID: 28356589
[No Abstract] [Full Text] [Related]
18. Trial watch: personalized medicines in late-stage development.
Milne CP; Garafalo S; Bryan C; McKiernan M
Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
[No Abstract] [Full Text] [Related]
19. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
[No Abstract] [Full Text] [Related]
20. Mark Fishman. Interview by Asher Mullard.
Fishman M
Nat Rev Drug Discov; 2012 Jan; 11(1):14-5. PubMed ID: 22212670
[No Abstract] [Full Text] [Related]
[Next] [New Search]
